Sugi Predict

Sugi Predict / Compounds / SCHEMBL4126209

SCHEMBL4126209

SCHEMBL4126209

CCOC(=O)c1ccc(N2CCC3(CC2)CCN(C2CCC2)CC3)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.55
▸ POLB P06746 4/20 0.55
▸ HPGD P15428 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ HRH3 Q9Y5N1 2/20 0.47
▸ PKM P14618 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ SIRT2 Q8IXJ6 1/20 0.44
▸ SIRT1 Q96EB6 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ MBTD1 Q05BQ5 1/20 0.43
▸ TP53BP1 Q12888 1/20 0.43
▸ L3MBTL4 Q8NA19 1/20 0.43
▸ L3MBTL3 Q96JM7 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ CACNA1B Q00975 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63892 0.89 ALDH1A1 (0.63) ALDH1A1POLBHPGDHTTHRH3
SCHEMBL6135228 0.87 ALDH1A1 (0.67) ALDH1A1POLBHPGDHTTHRH3
SCHEMBL63474 0.86 ALDH1A1 (0.59) ALDH1A1POLBHPGDHTTSMN1; SMN2
SCHEMBL2951762 0.86 HPGD (0.55) ALDH1A1POLBHPGDHTTSMN1; SMN2
SCHEMBL6134915 0.85 ALDH1A1 (0.65) ALDH1A1POLBHPGDHTTSMN1; SMN2
SCHEMBL6132930 0.85 HPGD (0.51) ALDH1A1HPGDHTTSMN1; SMN2MEN1
SCHEMBL4936807 0.84 HRH3 (0.51) POLBHRH3PKMKMT2ALMNA
SCHEMBL64407 0.84 ALDH1A1 (0.58) ALDH1A1POLBHPGDHTTSMN1; SMN2
SCHEMBL4136511 0.83 KMT2A (0.62) ALDH1A1HPGDHRH3MEN1KMT2A
SCHEMBL6369256 0.82 ALDH1A1 (0.61) ALDH1A1POLBHPGDHTTHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 — — EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 — — US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 — — WO claimed
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 — — EP disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 — — US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 — — US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 — — US disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 ALDH1A1 734/4885POLB 3797/4885HPGD 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.